Tyra Biosciences' (TYRA) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Tyra Biosciences' stock has been reaffirmed with a sell (D-) rating by Weiss Ratings, indicating bearish sentiment among analysts.
• Despite the negative ratings from Weiss, other firms such as Raymond James and Oppenheimer have issued strong-buy and outperform ratings, with target prices of up to $36.00.
• The company's shares recently traded at $13.63, reflecting a 1.9% increase, and it has a market capitalization of $726.48 million.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Several other brokerages have also commented on TYRA. Raymond James Financial began coverage on Tyra Biosciences in a research report on Tuesday, September 2nd. They set a "strong-buy" rating and a $35.00 target price on the stock. Oppenheimer reissued an "outperform" rating and issued a $36.00 price target on shares of Tyra Biosciences in a research report on Wednesday, September 10th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, August 22nd. Finally, Wall Street Zen raised shares of Tyra Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.86.

Tyra Biosciences Trading Up 1.9%

Shares of Tyra Biosciences stock traded up $0.26 during mid-day trading on Wednesday, hitting $13.63. 98,464 shares of the stock were exchanged, compared to its average volume of 185,181. The stock has a market capitalization of $726.48 million, a price-to-earnings ratio of -7.66 and a beta of 1.11. The company has a 50-day simple moving average of $12.06 and a 200 day simple moving average of $10.52. Tyra Biosciences has a twelve month low of $6.42 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.06. Equities research analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. boosted its position in shares of Tyra Biosciences by 23.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 301,801 shares of the company's stock valued at $2,807,000 after purchasing an additional 57,556 shares in the last quarter. Polar Asset Management Partners Inc. increased its stake in Tyra Biosciences by 27.1% during the 1st quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company's stock worth $1,314,000 after buying an additional 30,134 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in Tyra Biosciences by 42.7% during the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock worth $110,000 after acquiring an additional 3,550 shares in the last quarter. Nuveen LLC purchased a new position in Tyra Biosciences in the first quarter valued at about $465,000. Finally, Rhumbline Advisers lifted its holdings in Tyra Biosciences by 7.2% in the 1st quarter. Rhumbline Advisers now owns 28,081 shares of the company's stock worth $261,000 after buying an additional 1,879 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.